Skip to main content
. 2009 Nov;1(3):183–205. doi: 10.1177/1758834009349119

Table 5.

Randomized phase III trial of temsirolimus, interferon-α or both in poor-risk metastatic renal cell cancer patients [Hudes et al. 2007].

Treatment PFS p value OS p value
Temsirolimus 3.7 0.0001 10.9 0.0069
Interferon-α 1.9 0.0019 7.3 0.6912
Interferon-α  + temsirolimus 3.7 8.4

OS, overall survival; PFS, progression-free survival.